Trintellix Approval History
FDA Approved: Yes (First approved September 30, 2013)
Brand name: Trintellix
Generic name: vortioxetine
Dosage form: Tablets
Previous Name: Brintellix
Company: Takeda Pharmaceutical Company Limited
Treatment for: Depression, Major Depressive Disorder
Trintellix (vortioxetine) is a multimodal antidepressant for the treatment of major depressive disorder (MDD).
Trintellix was first approved as Brintellix (vortioxetine) on September 30, 2013.
On May 2, 2016, Takeda Pharmaceuticals U.S.A., Inc. announced that Brintellix (vortioxetine) would be marketed under the new name Trintellix (vortioxetine) effective June 2016. The name change came after reports of name confusion in the marketplace between Brintellix and the anti-blood clotting therapy Brilinta (ticagrelor).
Development History and FDA Approval Process for Trintellix
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.